Note:Don't Try To Use Some Other Fluconazole Manuals Before You Read This Zero Cost Documentation

Ancestry negatively (P?Rucaparib ic50 Inc. ""5318" "QIANLI MA, QIAO ZHANG, CHANGZHENG WANG Institute of Respiration, Fluconazole Xinqiao Hospital, Third Military Medical University, Chongqing, China Introduction?The low treatment adherence of patients with Asthma is one of the biggest challenge in Asthma management. Although there are lot of research performed, most of them were designed to assessment the adherence and corresponding to influence factors in current. This is a research designed for assessing the reasons for non-adherence patients who had received treatment based on guideline, in current and next 24 weeks, by telephone follow-up. Methods?This is a 24 weeks, prospective, multicenter, telephone follow-up study performed in 12 hospitals from February to October in 2012. The interviewing and administering questionnaires have been performed by the telephone follow-up. (Registration Selleck ALK inhibitor No: ChiCTR-OCH-12002744) Results?A total of 1278 adults and 310 adolescents with asthma were enrolled in this study. The majority of patients were female (56.3%) with a mean age of 46.9?��?12.5 years in adults. There were 53.9% female and the mean age of 6.8?��?2.8 years in adolescents. After 24 weeks follow-up, 37.6% adults with asthma complied with treatment and 54.8% adolescents complied. The major reasons for non-adherence were ��My symptoms has get control, I am no need to adherence treatment.��(50.5%), ��I feels the treatment is useless.�� (16.8%) and ��Too expensive�� (10.5%) in adults and with similar results in adolescents. There were 68.0% adults withdrawal treatment, and 40.4% adolescents withdrawal treatment. Conclusions?In CHINA, the inadequate understanding of the asthma treatment target is the most important reason for non-adherence rather than the economic burden. Disease education should be pay more attention in chronic management. MASAYUKI HOJO, JUNKO HIRASHIMA, NAHOKO SATO, MOTOYASU IIKURA, HARUHITO SUGIYAMA Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan Background and Aim of Study?Salmeterol/Fluticasone combination inhaler (SFC) is currently most widely used inhaled drugs for the maintenance therapy against mild to moderate persistent asthmatics in the world.